COMMUNIQUÉS West-GlobeNewswire

Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
26/03/2024
LEXINGTON, Mass., March 26, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, has entered into an employment agreement with Toby [...]
Korro Reports Full Year 2023 Financial Results and Highlights Recent Progress
26/03/2024
On track for regulatory filing for First-in-Human study of KRRO-110 in Alpha-1 Antitrypsin Deficiency (AATD) patients anticipated in the second half of 2024 Demonstrated the versatility of Korro’s RNA editing platform [...]
Galapagos appoints Andrew Dickinson as Non-Executive Non-Independent Director to its Board
26/03/2024
Mechelen, Belgium; 26 March 2024, 21:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that during its meeting of 26 March 2024, the Board of Directors appointed Mr. Dickinson as Non-Executive Non- [...]
BioAtla Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Progress
26/03/2024
CAB-CTLA-4 (BA3071) Phase 1 study cleared dose-limiting toxicity (DLT) observation period with 700 mg (10 mg/kg); initial Phase 2 monotherapy data readout anticipated in 2Q 2024 and in combination with pembrolizumab in [...]
Aptose Reports Results for the Fourth Quarter and Full Year 2023
26/03/2024
Tuspetinib to Advance to TUS+VEN+HMA Triplet Therapy Pilot Study in 1L AML Tuspetinib Continues Broad Activity Across Mutations with Excellent Safety Profile Luxeptinib G3 Formulation Achieves Desired Levels and [...]
INmune Bio Inc. to Report Fourth Quarter 2023 Financial Results and Provide a Corporate Update on Thursday, March 28
26/03/2024
Management to host conference call and webcast at 4:30 pm ET on that day Boca Raton, Florida, March 26, 2024 (GLOBE NEWSWIRE) -- INmune Bio Inc . (NASDAQ: INMB) (the “Company”), a clinical-stage immunology and [...]
argenx Announces Annual General Meeting of Shareholders on May 7, 2024
26/03/2024
March 26, 2024 Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that [...]
Surgery Partners, Inc. Announces Pricing of New Senior Notes Offering
26/03/2024
BRENTWOOD, Tenn., March 26, 2024 (GLOBE NEWSWIRE) -- Surgery Partners, Inc. (NASDAQ:SGRY) (“Surgery Partners” or the “Company”) today announced that its wholly-owned subsidiary, Surgery Center Holdings, Inc. (the “ [...]
2023 Shareholders General Meeting
26/03/2024
Press release Ecully, March 26, 2024 – 8.00 p.m. Minutes of the General Meeting of March 25, 2024 The Combined General Meeting (Ordinary and Extraordinary) of Spineway shareholders was held on first notice on Monday, [...]
Assemblée Générale 2023
26/03/2024
Communiqué de presse Ecully, le 26 mars 2024 – 20h Compte-rendu de l’Assemblée Générale du 25 mars 2024 L'Assemblée Générale Mixte (Ordinaire et Extraordinaire) des actionnaires de Spineway s'est tenue sur première [...]
LifeLabs Unveils At Home Kit Program, Empowering Ontarians to Prioritize Health with Ease
26/03/2024
Toronto, Ontario, March 26, 2024 (GLOBE NEWSWIRE) -- LifeLabs, a leading provider of laboratory diagnostic services, is thrilled to introduce our latest offering: At-Home Self-Collection Kits. LifeLabs’ At Home Kit [...]
HeartFlow Initiates DECIDE Registry to Evaluate Utility of HeartFlow AI-Enabled Plaque Analysis for Patients with Suspected Coronary Artery Disease
26/03/2024
The largest prospective registry of its kind will build upon clinical data supporting the use of plaque insights to empower clinical decision making for patients with suspected coronary artery disease MOUNTAIN VIEW, [...]
Information on the Total Number of Voting Rights (Denominator) following Conversion Notices from Atlas
26/03/2024
Information on the Total Number of Voting Rights (Denominator) following Conversion Notices from Atlas Atlas Special Opportunities, LLC has converted 6 convertible bonds in Oxurion resulting in a EUR 150,000 capital [...]
Roche receives FDA approval for the first molecular test to screen for malaria in blood donors
26/03/2024
The cobas Malaria test is the first FDA-approved molecular test to screen U.S. blood donors for malaria Malaria is a serious and potentially fatal parasitic infection most commonly transmitted by mosquitoes that can [...]
Psyence Group Announces the Closing of the Previously Announced Strategic Restructuring of Its Non-Clinical Business
26/03/2024
TORONTO, March 26, 2024 (GLOBE NEWSWIRE) -- Further to the announcement by Psyence Group Inc (" Psyence " or the " Company ") (CSE:PSYG) of its plans for the strategic restructuring of its non-clinical business through [...]
Alterity Therapeutics Receives a A$3.9 Million Research & Development Tax Incentive Refund
26/03/2024
MELBOURNE, Australia and SAN FRANCISCO, March 27, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease [...]
Hapbee Announces Closing of Private Placement
26/03/2024
Company Raises $2.8 Million From Qualified Investors to Fund Product Development, Market Expansion and Manufacturing VANCOUVER, British Columbia, March 26, 2024 (GLOBE NEWSWIRE) -- Hapbee Technologies , Inc. (TSXV: HAPB [...]
RENNOVA HEALTH, INC., ANNOUNCES THE EXPIRATION OF WARRANTS TO PURCHARE OVER FOUR HUNDRED BILLION COMMON SHARES
26/03/2024
WEST PALM BEACH, Fla., March 26, 2024 (GLOBE NEWSWIRE) -- Rennova Health, Inc. (OTC: RNVA) announces that certain Series A, B and C warrants to purchase approximately 403,788,906,644 shares of common stock expired on [...]
Grant Christie Joins Acentra Health as Senior Vice President of Market Strategy and Solutions
26/03/2024
MCLEAN, Va., March 26, 2024 (GLOBE NEWSWIRE) -- Acentra Health, a Virginia-based technology solutions and clinical services company dedicated to helping government healthcare agencies accelerate better health outcomes, [...]

Pages